Patient-based prospective real-world data analysis shows that the duration of treatment interruptions with subsequent resumption of idelalisib therapy can vary from days to months.

26. Juli 2019

Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., von Troostenburg, A., Ramroth, H., Abenhardt, W., Rummel, M., 2019.

HemaSphere 3 (PS1163), 528–529. https://doi.org/10.1097/01.HS9.0000562936.05518.43

Abstract